Introduction. TREATMENT BASED ON TUMOR SIDEDNESS IN mCRC: THE EVIDENCE AND PRACTICAL APPLICATION.

Slides:

Advertisements

Similar presentations

Synopsis of FDA Colorectal Cancer Endpoints Workshop Michael J. O’Connell, MD Director, Allegheny Cancer Center Associate Chairman, NSABP Pittsburgh, PA.

Advertisements

CRITICAL READING OF THE LITERATURE RELEVANT POINTS: - End points (including the one used for sample size) - Surrogate end points - Quality of the performed.

Advanced Cancer Topics Journal Review 4/16/2009 AD.

The Colorectal Cancer Center Jena Gharbi A, Settmacher U. Department of General, Visceral and Vascular Surgery, Friedrich-Schiller-University Jena

Mace L. Rothenberg, M.D. Professor of Medicine Ingram Professor of Cancer Research Biomarkers in Colorectal Cancer Management: KRAS Mutations and EGFR.

Dr. Marco Matos JOURNAL CLUB GCUH 4/07/14.

Presented By Alan Venook at 2016 ASCO Annual Meeting

CCO Independent Conference Coverage

8th Mucscat International Oncology conference. Muscat, Oman

Prognostic Factors for First-line Chemotherapy + Bevacizumab or Cetuximab in Metastatic Colorectal Cancer CCO Independent Conference Highlights* of the.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Individualizing Treatment Options in Advanced ER-Positive Breast Cancer.

CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: Implementing Paradigms in Clinical Practice.

COPD by the Guidelines.

Challenges in RAS Wild-Type mCRC

New ESMO Guidance on Tumor Sidedness in mCRC

Monitoring and Management of Adult Relapsed/Refractory Acute Promyelocytic Leukemia.

Clinical Considerations in the Management of EGFR-Mutated Advanced NSCLC.

A Paradigm Shift From One-Size-Fits-All to Tailor-Made Therapy for Metastatic Colorectal Cancer.

What to Do Next: Sequencing of Therapy in Patients With Metastatic CRC

Introduction. TREATMENT BASED ON TUMOR SIDEDNESS IN mCRC: THE EVIDENCE AND PRACTICAL APPLICATION.

The Nurse View.

Progression After Cancer Immunotherapy in Advanced NSCLC

The Genomics of Cancer and Molecular Testing:

Colorectal Cancer: Current “Standard” Uses for Molecular Testing

The Nurse View: Overcoming Challenges Associated With Cancer Immunotherapy.

The Nurse View: Updates in the Management of Metastatic Colorectal Cancer.

Optimizing Outcomes in the Management of GIST

Introduction. For Pulmonologists by Pulmonologists: Diagnosis of NSCLC in an Age of Biomarkers.

A proposed treatment model for the decision-making process when choosing between cetuximab continuation vs rechallenge. aTypically patients with left-sided,

THE CONTINUUM OF CARE IN mCRC: OPTIMIZING USE OF EGFR ANTIBODIES

T790M Mutation-Positive NSCLC: A Multidisciplinary Case Conference

Counseling Patients About Germline BRCA Mutations

The Evolving Role of Immunotherapy in NSCLC

Liquid Biopsy for RAS Screening in CRC: How Can We Successfully Implement This New Paradigm?

Volume 150, Issue 4, Pages (April 2016)

Basics of Immunotherapy Potential Therapeutic Targets.

Best Practices in Metastatic Colorectal Cancer

Managing gBRCA-Positive Metastatic Breast Cancer

Management Challenges in CLL

The Nurse View: Targeted Therapies for the Patient With Metastatic Colorectal Cancer.

From Symptom Management to Communication in Advanced GI Cancers

When Is Biologic Therapy Appropriate for HS?

Patient-Centered Management in BRAF-Positive Metastatic Melanoma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.

Patient-Centered Management in Advanced Non-Small Cell Lung Cancer

Published online September 20, 2017 by JAMA Surgery

Challenges in LA SCCHN.

What's on the Horizon? Assessing New First-Line Paradigms for AML Patients Ineligible for Intensive Chemotherapy.

How Can Precision Medicine in Oncology Refine Best Treatment Approach?

Multidisciplinary Management in Non-Small Cell Lung Cancer (NSCLC)

THE CONTINUUM OF CARE IN mCRC: OPTIMIZING USE OF EGFR ANTIBODIES

New Insights on Treatment Strategies for mCRC:

Quality Improvement and Molecular Profiling in Advanced Non-Small Cell Lung Cancer.

This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.

Ali Shamseddine,MD,FRCP

Clinical Considerations in the Use of Checkpoint Inhibitors Breast Cancer.

The Nurse View: Spotlight on EGFR-Mutated NSCLC

Finding the Right Sequence in Patients With EGFR-Mutated NSCLC

What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer

Clinical Pearls in the Management of Patients With Advanced Non-Small Cell Lung Cancer.

Evaluating the Totality of Evidence

The Nurse View.

Changing Paradigms in Relapsed/Refractory Indolent NHL

Molecular heterogeneity drives secondary resistance to anti-EGFR therapies in mCRC. Molecular heterogeneity drives secondary resistance to anti-EGFR therapies.

Uncovering the Right Sequence

Consort diagram of the study depicting the process of patients’ selection. Consort diagram of the study depicting the process of patients’ selection. A.

Presentation transcript:

TREATMENT BASED ON TUMOR SIDEDNESS IN mCRC: THE EVIDENCE AND PRACTICAL APPLICATION

Introduction

Pathological Distinctions Between CRC Tumors

mCRC: Sidedness and Outcomes

Relevance of PTL in mCRC: What Is the Impact on Clinical Decisions?

Case 1: Left-Sided mCRC

Treatment Options for Left-Sided mCRC

Treatment-Related AEs Associated With EGFR Inhibitors

Chemotherapy ± Cetuximab in Patients With Resectable Colorectal Liver Metastasis: New EPOC Study

ESMO Consensus Guidelines for the Management of Patients With mCRC

NCCN Guidelines for the Treatment of Colon Cancer

Case 2: Right-Sided CRC

PTL Is Predictive of Treatment Response

EGFR Inhibitor-Associated Dermatologic Toxicities

Molecular Biomarker Testing for the Evaluation of CRC

Transverse CRC: Shared Embryology, Pathology, and Genetics

The Use of Tumor Sidedness as a Potential Surrogate Marker

Concluding Remarks

Abbreviations

Abbreviations (cont)